Serina Therapeutics, Inc.
SERAMEXHealthcare● Active
$1.90
+$0.02(+1.06%)
Market Cap$20583333
P/E Ratio—
52W High$7.92
52W Low$1.22
Serina Therapeutics, Inc. (SER) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SER · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.58
Est. -$0.44 · -31.8%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS
SER reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q4 FY2026 | Nov 9, 2026 | -$0.46 | — | — | — | — | — |
| ◌ Q3 FY2026 | Aug 7, 2026 | -$0.46 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.44 | -$0.58 | -31.8% | — | — | — |
| ▲ Q1 FY2026 | Mar 25, 2026 | -$0.50 | -$0.31 | +38.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.47 | -$0.45 | +4.3% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.36 | -$0.66 | -83.3% | $0.00B | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.62 | -$0.49 | +21.0% | — | — | — |
| ▼ Q1 FY2025 | Mar 24, 2025 | $0.42 | -$0.27 | -164.3% | — | — | — |
Q4 FY2026
Nov 9, 2026
EPS Actual
—
EPS Est.
-$0.46
EPS Surpr.
—
Revenue
—
Q3 FY2026
Aug 7, 2026
EPS Actual
—
EPS Est.
-$0.46
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.58
EPS Est.
-$0.44
EPS Surpr.
-31.8%
Revenue
—
Q1 FY2026
Mar 25, 2026Beat
EPS Actual
-$0.31
EPS Est.
-$0.50
EPS Surpr.
+38.0%
Revenue
—
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.45
EPS Est.
-$0.47
EPS Surpr.
+4.3%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.66
EPS Est.
-$0.36
EPS Surpr.
-83.3%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.49
EPS Est.
-$0.62
EPS Surpr.
+21.0%
Revenue
—
Q1 FY2025
Mar 24, 2025Miss
EPS Actual
-$0.27
EPS Est.
$0.42
EPS Surpr.
-164.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.28 | $-0.28 | $-0.28 | 1 |
| Q3 FY2027 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q2 FY2027 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q1 FY2027 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q4 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q3 FY2026 | $-0.46 | $-0.46 | $-0.46 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -31.8% | $1.56 | $1.72 | +10.26% |
| ▲ Q1 FY2026 | Mar 25, 2026 | +38.0% | $2.43 | $3.03 | +24.69% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +4.3% | $4.02 | $3.92 | -2.49% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -83.3% | $5.51 | $5.10 | -7.44% |
| ▲ Q2 FY2025 | May 8, 2025 | +21.0% | $5.75 | $5.75 | +0.00% |
| ▼ Q1 FY2025 | Mar 24, 2025 | -164.3% | $4.80 | $4.84 | +0.83% |
| — Q4 FY2024 | Nov 12, 2024 | — | $5.27 | $5.19 | -1.52% |
| — Q3 FY2024 | Aug 9, 2024 | — | $7.53 | $7.14 | -5.18% |
Q2 FY2026+10.26%
Report Date
May 14, 2026
EPS Beat/Miss
-31.8%
Price Before
$1.56
Price After
$1.72
Q1 FY2026+24.69%
Report Date
Mar 25, 2026
EPS Beat/Miss
+38.0%
Price Before
$2.43
Price After
$3.03
Q4 FY2025-2.49%
Report Date
Nov 13, 2025
EPS Beat/Miss
+4.3%
Price Before
$4.02
Price After
$3.92
Q3 FY2025-7.44%
Report Date
Aug 11, 2025
EPS Beat/Miss
-83.3%
Price Before
$5.51
Price After
$5.10
Q2 FY2025+0.00%
Report Date
May 8, 2025
EPS Beat/Miss
+21.0%
Price Before
$5.75
Price After
$5.75
Q1 FY2025+0.83%
Report Date
Mar 24, 2025
EPS Beat/Miss
-164.3%
Price Before
$4.80
Price After
$4.84
Q4 FY2024-1.52%
Report Date
Nov 12, 2024
EPS Beat/Miss
—
Price Before
$5.27
Price After
$5.19
Q3 FY2024-5.18%
Report Date
Aug 9, 2024
EPS Beat/Miss
—
Price Before
$7.53
Price After
$7.14
Avg Beat Reaction+7.40%
Avg Miss Reaction+1.22%
Beat Rate3 / 8 quarters
Largest Move+24.69% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SER ends December
Serina Therapeutics, Inc. (SER) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.58 — missing the analyst consensus of $-0.44 by -31.8%. The next SER earnings date is expected around September 1, 2026.
Each quarter, investors track SER earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SER revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SER's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SER earnings · 5 questionsSerina Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. SER typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SER historically reports after market close (AMC).
SER earnings datewhen is SER earningsSER next earnings datewhen does SER report earningsSER earnings calendar
▸ Source: FMP · Serina Therapeutics, Inc. SEC filings · US GAAP · Serina Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026